Hospices need long-term funding plan, minister says
Labour Minister of State for the Department of Health and Social Care Stephen Kinnock last week announced £75 million to be shared by 170 hospices across the country.
Unlike the NHS, hospices are not fully funded by the state and rely on charity contributions for about two thirds of their funding, with the sector reporting an estimated shortfall of £60m last financial year.
Speaking at Wigan & Leigh Hospice in Greater Manchester, which received £500,000 from the funding pool, Kinnock said the government needed to cover a bigger portion of the cost.
"We do warmly welcome the way that people step up and get involved in supporting their local hospice, but I absolutely recognise that we, the Department for Health and Social Care, we need to step up and do our bit," he said.
The £75 million is in addition to a £25 million package the government distributed in February.
Hospices in the north west of England provide end-of-life and palliative care for some 23,000 people in the region, with demand and costs continuing to rise.
Geoff Crook, 68, had been receiving care at Wigan & Leigh Hospice earlier this month alongside his wife Margaret, allowing him to be by her side for her final moments.
"I don't think we would have been able to cope if we hadn't had anything like this, I really don't" he said.
Wigan & Leigh Hospice chief executive Jo Carby said the £500,000 would be used to fix the building's leaking roof and to put in a new heating system and memory garden.
But she said it was "not enough" and that hospices needed a longer-term solution.
"Everyone's struggling for money essentially in our borough and it is unfair for us to be asking the people of Wigan to be spending more of their money when they already have less to spend in order to keep the hospice going," she said.
Kinnock said the government was currently negotiating how much funding would be allocated to palliative and end-of-life care in its three-year-spending review settlement.
He said: "As soon as we have that I want to see that long-term plan to take us at least through to the end of this parliament.
Kinnock said the government was determined to find "long-term solutions".
"I have made it very clear to my team of officials in [the Department] that I don't want another last-minute scramble at the end of the financial year to, with a sticking plaster, solve a problem for the short term," he said.
Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
Campaigners warn NHS 'cannot afford hospice cuts'
Hospice fears pre-Christmas funding plans shelved
Campaigner takes hospice petition to Downing Street
Hospices facing funding crisis
Related internet links
Department of Health & Social Care
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Noom Launches Microdose GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program
70% of Noom members receiving microdoses of GLP-1 with lifestyle support report no side effects, while experiencing significant weight loss and overall health gains The program addresses all three major barriers to bending the obesity curve in the US: excessive US prices of medication, medication side effects, and sustainable lifestyle change NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate. The Microdose GLP-1Rx Program is priced at $119 to start, followed by $199 per month, which includes medication, if prescribed, and Noom's powerful GLP-1 Companion, providing clinical care, coaching, and a personalized healthy habits program. The US obesity rate, after decades of unstoppable growth, has at last started to plateau, but at a level that continues to lead the developed world. The US rate of obesity stands at more than 40% versus the UK at 26%, Germany at 23%, and France at 10%. Meanwhile, GLP-1 medications cost as much as 5x more in the US than in these same countries. Three core barriers prevent broader and faster progress: medication cost, medication side effects, and the lack of sustainable behavior change. Noom's Microdose GLP-1Rx Program directly addresses each of these three barriers, to help meaningfully bend the obesity curve. Only affordable GLP-1s and Behavior Change will bend this curve. Noom's physician-designed program employs a 'low and slow' titration approach with microdoses that are a fraction of conventional maintenance doses. Noom's data has shown that members on microdoses are far less likely to have destabilizing side effects. In fact, 70% of Noom members receiving microdoses report no side effects at all. At the same time, members achieve up to 11 pounds of weight loss in 30 days and up to 17 pounds in 60 days at microdose dosages. Meanwhile, studies indicate the vast majority–more than 70%–of patients on standardized protocols experience side effects. 'In the Microdose GLP-1Rx Program, we set out to virtually eliminate side effects for the vast majority, so that more than 70% of people would encounter no side effects. In both my clinical experience and evidence in published studies, it is clear that many people discontinue GLP-1 treatment because of side effects,' said Dr. Jeffrey Egler, Chief Medical Officer at Noom. 'The Noom Microdose GLP-1Rx Program was designed to address this issue by introducing GLP-1s gradually and sustaining them at a microdose level, as part of a larger holistic behavior change platform, which we call our GLP-1 Companion. This approach helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the United States.' Noom's Microdose GLP-1Rx Program is based on scientific principles: Self-efficacy boosts success with healthy habits. GLP-1 medication makes it easier to adopt healthy habits, while healthy habits improve health outcomes. Members who engage with Noom's GLP-1 Companion achieve 10% weight loss by month 4 at twice the rate compared to those who are not engaged. Noom members on GLP-1s actually log more meals, weigh in more often, and log more exercise by their second month than those on Noom without a GLP-1. Strong weight loss outcomes at lower doses are both achievable and well established in the literature. A 2,700‑person real‑world study presented at the 2025 European Congress on Obesity showed an average 16% weight‑loss over 64 weeks at microdose levels of semaglutide. Meanwhile, another study in The New England Journal of Medicine shows just 33% of the dose of one popular GLP-1 drove 72% of the weight loss at week 72 with a lower side effect profile. The benefits from GLP-1s extend beyond weight. Recent analyses presented at the National Lipid Association's 2025 Scientific Sessions highlighted cardiovascular, renal, and metabolic gains from GLP‑1s that appear partly independent of the amount of weight loss. Other studies show a similar impact on inflammatory markers independent of weight loss.. Meanwhile, other studies demonstrate a reduction in compulsive behaviors like drinking and gambling. Taken together, the evidence is clear: microdoses of GLP-1 paired with microhabits can unlock outsized health benefits. What is a Microdose? Noom defines a microdose as a dose of medication that is a fraction – 25% or less – of the typically prescribed maintenance dose. Noom's microdose dosing schedule is not one-size-fits-all. It accesses doses lower than the usual starter doses as well as additional doses up to 25% of the standard maintenance dose. Within that band, the exact dosage schedule is established one member at a time: our physician-prescribed protocol, aided by Noom's SmartDose experience, guides members to the lowest dose that achieves health goals. Factors influencing that decision include BMI, weight loss speed, side effect profile, and other health data. 'Noom has a unique, proprietary dataset that permits the level of deep personalization that our program deploys,' continued Dr. Jeffrey Egler. 'The Noom program has comprehensive data on patient health, injection dates, side effects, and weight-loss speed, and we bring that data to bear to personalize the dosing to maximize outcomes and adherence not just to the medication, but to our Noom microhabits program.' While many eligible GLP-1 users are deterred from starting medication due to fear of incurring side effects, others are challenged by high medication costs. Among those who do start using GLP-1s, over 50% stop due to costs, and as many as 36% stop due to side effects. Noom's Microdose GLP-1Rx Program bridges this gap by offering a more personalized, tolerable path to treatment. It is built on a guiding principle of using the lowest effective dose first. Rather than increasing medication on a fixed schedule, Noom's physician-designed protocol adjusts dosing based on each patient's individual progress and response. This approach enables personalized care that supports meaningful weight loss while minimizing side effects and helping more people adhere to the treatment. GLP-1s and Weight Loss Accessibility - Solving Today's High-Priced Drug Crisis GLP-1 medications continue to be significantly more affordable around the world than in the United States. Popular GLP-1 medications are priced around $99 a month in many developed nations, but at $499 a month to cash-pay patients in the United States. Cost is a major barrier to accessibility in the US, where the price of medications and healthcare services are often much higher than internationally. Noom's accessibly priced Microdose GLP-1Rx Program, starting at $119, builds on the company's advocacy efforts on behalf of patients in the US. In April 2025, Noom sponsored a back cover advertisement in the The Wall Street Journal calling for the creation of a High-Priced Drug List by HHS. The High-Priced Drug List is a market-based solution enabling competition from the country's 503A and 503B pharmacies when medications are priced higher in the United States compared to other developed countries. In addition to the launch of Noom's Microdose GLP-1Rx Program, on Wednesday, July 30th, at an event at The White House, Noom pledged to make available a free tier of Noom to all Americans – regardless of income or BMI. The free tier will launch before the end of the summer and deliver a personalized experience focused on building healthy habits in nutrition, physical activity, and stress reduction. 'Medication alone will not end the obesity epidemic. Lifestyle change is essential,' said Cook. 'By offering a no-cost way for anyone to build healthy habits with Noom, we can reach millions more Americans with the tools to help them live better longer. Pairing that with our new microdose GLP-1 program will help bend the curve on obesity rates in the United States.' Noom Microdose GLP-1Rx Program includes: Microdose GLP-1 medication, if prescribed Full access to the Noom GLP-1 Companion behavior and microhabits program 24/7 access to message doctors and care coordinators Noom premium 1:1 health coaching Prescription home delivery Pricing: $119 to start and then $199 per month Looking Ahead to Longevity 'GLP-1s with Noom's microhabit program represent a modern treatment for the ills of modernity,' said Cook. 'We help people sustain a healthy weight in a food environment engineered for dopamine-hits and excess consumption. By helping people limit compulsive eating and drinking, motivate movement, and reduce chronic inflammation, which we know GLP-1s can do, we promote a higher quality life.' 'The latest science demonstrates that we should be thinking about GLP-1 medication differently,' said Dr. Jeffrey Egler. 'GLP-1s are no longer only useful for weight loss and diabetes – they are critical for building metabolic resilience and reducing inflammation, making them a powerful component of whole-person, lasting health. For our patients, we see GLP-1s as the first step in an extraordinary journey to true vitality.' The Microdose GLP-1Rx Program is available to Americans in 45 states at the following link: About Noom: Noom is the leading whole-person health platform, combining personalized medication with psychology and habit science to help people take control of their metabolic health, weight, and longevity. Noom Health partners with top health plans and employers to offer a suite of solutions, including Noom Med, Noom Weight, Noom GLP-1 Companion, and Noom Diabetes Management and Diabetes Prevention Program to millions. Founded on a mission to empower everyone everywhere to live better longer, Noom has received multiple National Institute of Health grants and was the first mobile app recognized by the CDC as a certified diabetes prevention program. With offices in New York City and Princeton, NJ, Noom has been named one of Inc.'s Best Places to Work, Quartz's Best Workplaces for Remote Workers, and Fortune's Best Workplaces in Technology. Learn more at subscribe to our blog, or follow us on Twitter and LinkedIn. Contact:Brandyn Bissingercomms@ Photos accompanying this announcement are available at: beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Washington Post
an hour ago
- Washington Post
Everybody wants your 5-star rating. Even your ear surgeon.
The stitches in Cory Lonas's head were fresh. His mind felt loopy coming down from anesthesia; he couldn't hear. It had only been 24 hours since Lonas underwent cochlear implant surgery when, through bleary eyes, the 39-year-old saw an email come in on his phone. How would he rate his experience at the hospital? How were his interactions with the doctors, the staff, the food? Would he recommend the hospital to a friend?
Yahoo
an hour ago
- Yahoo
CareCloud's TalkEHR Approved for Use by Critical Access Hospitals, Unlocking $1.5B+ Inpatient Market
SOMERSET, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) ('CareCloud' or the 'Company'), a leading provider of healthcare technology and generative AI solutions, today announced that its electronic health record ('EHR') platform has achieved ONC Health IT Certification specifically for Critical Access Hospitals ('CAHs'), a milestone officially granted on August 1, 2025. This certification marks CareCloud's strategic entry into the inpatient EHR market, unlocking access to a $1.5 billion+ opportunity across more than 1,300 CAHs increasingly seeking modern, cloud-based systems designed for their unique operational and clinical needs. A recent Black Book Research study reveals that over half of rural and CAHs plan to replace their legacy EHR systems by 2026, citing cost predictability, cloud deployment, interoperability, and reduced IT burden as top priorities. CareCloud's newly certified solution is designed to meet this demand, offering flexibility, compliance, and embedded AI tools at a sustainable cost. 'This certification is far more than a checkbox, it's our entrance into a healthcare segment ready for innovation,' said A. Hadi Chaudhry, Co-CEO of CareCloud. 'We've built an AI-powered, cloud-based platform purpose-built to address the clinical, operational, and regulatory needs of rural hospitals and help them move beyond outdated, high-maintenance systems.' Modernizing Rural Healthcare with Cloud and AI Critical Access Hospitals play an essential role in rural care delivery but have long faced challenges accessing modern, interoperable EHR solutions. CareCloud's platform closes that gap by offering: Certified compliance for Medicare and federal reporting programs Support for inpatient, outpatient, and swing-bed workflows Built-in AI tools for documentation, clinical decision support, and revenue optimization A cloud-based architecture that reduces IT overhead and improves deployment flexibility This aligns closely with what CAHs say they want: subscription-based solutions, streamlined regulatory compliance, and automation that lightens the administrative burden on their staff. By meeting the specific needs of CAHs with a flexible, cloud-based solution, CareCloud is furthering its mission to support providers across the full continuum of care. About CareCloud CareCloud brings disciplined innovation to the business of healthcare. The Company offers a comprehensive suite of cloud-based technology and AI solutions for medical groups and health systems, including revenue cycle management, practice management, telehealth, and now a certified inpatient EHR solution for CAHs. Visit Follow CareCloud on LinkedIn, X and Facebook. For additional information, please visit our website at To listen to video presentations by CareCloud's management team, read recent press releases and view the latest investor presentation, please visit Disclaimer This press release is for information purposes only and does not constitute an offer to sell or solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Forward-Looking Statements This press release contains various forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as 'may,' 'might,' 'will,' 'shall,' 'should,' 'could', 'intends,' 'expects,' 'plans,' 'goals,' 'projects,' 'anticipates,' 'believes,' 'seeks,' 'estimates,' 'predicts,' 'possible,' 'potential,' 'target,' or 'continue' or the negative of these terms or other comparable terminology. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management's expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, and the expected results from the integration of our acquisitions. Past operational or stock price performance is not an indication of future performance. These forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry's) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to the Company's ability to manage growth, migrate newly acquired customers and retain new and existing customers, maintain cost-effective global operations, increase operational efficiency and reduce operating costs, predict and properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards, compete with other companies' products and services competitive with ours, and other important risks and uncertainties referenced and discussed under the heading titled 'Risk Factors' in the Company's filings with the Securities and Exchange Commission. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made. SOURCE CareCloud Company Contact:Norman RothInterim Chief Financial Officer and Corporate ControllerCareCloud, Investor Contact:Stephen SnyderCo-Chief Executive OfficerCareCloud, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
